SciTransfer
Organization

NUTRILEADS BV

Dutch nutraceutical SME developing clinically validated health ingredients targeting the gut microbiome and mucin-glycobiology interface.

Technology SMEfoodNLSMENo active H2020 projectsThin data (2/5)
H2020 projects
2
As coordinator
1
Total EC funding
€2.8M
Unique partners
13
What they do

Their core work

NutriLeads is a Dutch nutraceutical SME based in Wageningen (the Netherlands' food science hub) developing bioactive health ingredients for functional foods and dietary supplements. Their flagship product, NL01, is a plant-derived ingredient that went through clinical validation and commercial launch preparation under EU funding. Their scientific work centers on how food compounds interact with the gut microbiome and intestinal mucin layer, making them a bridge between food ingredient R&D and clinical nutrition.

Core expertise

What they specialise in

Bioactive health ingredient developmentprimary
1 project

Coordinated the EUR 2.5M NUTRI-NEED project (2018-2020) for final development, clinical validation and market launch of the NL01 health ingredient.

Clinical validation of nutraceuticalsprimary
1 project

NUTRI-NEED explicitly covered clinical validation as a core work package before commercial launch.

Glycobiology and gut microbiota interactionsecondary
1 project

Industry partner in SWEET CROSSTALK MSCA-ITN (2019-2023), training glycoscientists on mucin, microbiota and structure-activity relationships.

Food-microbiome sciencesecondary
1 project

SWEET CROSSTALK focuses on glycocodes at the human gut interface, directly relevant to their ingredient pipeline.

Evolution & trajectory

How they've shifted over time

Early focus
Health ingredient commercialisation
Recent focus
Gut microbiome glycobiology

In 2018-2020 the company focused purely on commercial execution — taking one ingredient (NL01) through final clinical trials and market launch under the SME Instrument. From 2019 onwards they branched into more fundamental science, joining a Marie Curie training network on glycobiology and mucin-microbiome interactions. The trajectory is clear: from single-product commercialisation toward building the scientific depth needed for a broader microbiome-ingredient pipeline.

Moving from a single validated ingredient toward a science-led microbiome ingredient platform, useful for partners working at the intersection of nutrition, clinical trials and gut health.

Collaboration profile

How they like to work

Role: consortium_leaderReach: European7 countries collaborated

NutriLeads operates in both modes: they led a solo-coordinator SME-2 project to bring their own product to market, then joined a larger training consortium (13 partners, 7 countries) as the industrial voice on glycobiology research. This combination of own-IP commercialisation plus selective partnership in fundamental science is typical of a product-focused SME that uses academic networks to stay scientifically sharp.

Collaborated with 13 unique partners across 7 countries, centred on the European gut-health and glycobiology research community. The Wageningen base ties them closely to the Dutch food science cluster.

Why partner with them

What sets them apart

Most SME-2 beneficiaries stop at commercialisation — NutriLeads doubled down by embedding their scientists in an ITN training network on the exact biology that underpins their products (mucin, microbiota, structure-activity). For a partner looking for an industrial counterpart that speaks both regulatory/clinical language and advanced glycoscience, they are a rare fit. Their Wageningen location places them inside one of Europe's densest food-and-nutrition research ecosystems.

Notable projects

Highlights from their portfolio

  • NUTRI-NEED
    EUR 2.5M SME Instrument phase-2 project they coordinated alone to clinically validate and launch their proprietary NL01 health ingredient.
  • SWEET CROSSTALK
    A Marie Curie training network on mucin and microbiota glycobiology — an unusually deep scientific engagement for a product-focused SME.
Cross-sector capabilities
healthmultidisciplinary
Analysis note: Only 2 H2020 projects and limited keyword data on the coordinator project; the ingredient composition and exact clinical indication of NL01 are not specified in the provided data, so product-level claims are kept deliberately high-level.